Compare Enveric Biosciences Inc (ENVB) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Schwab US Large Cap Growth ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Schwab US Large Cap Growth ETF trades at $36.59 (market cap $65.76B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 9829.6× Enveric Biosciences Inc's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| ENVB | SCHG | |
|---|---|---|
Market Cap | $6.69M | $65.76B |
Volume | 41,141 | 8,114,853 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $36.93 |
52-Week Low | $1.27 | $28.10 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SCHG trades at $36.87, down slightly by 0.16% today, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF maintains strong institutional interest despite recent position adjustments by some wealth managers. Recent media coverage highlights SCHG's low-cost growth exposure and historical performance advantages over broader market indices.
The outlook remains positive given SCHG's focus on large-cap growth stocks and competitive expense ratio, though concentration risk in top holdings and potential market volatility present challenges. Long-term growth prospects appear favorable based on historical returns and continued investor appetite for growth-oriented strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
